Lapaquistat acetate - CAS 189060-13-7
Catalog number: B0084-061834
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Lapaquistat acetate, also referred as TAK475, is a squalene synthase inhibitor. As a cholesterol-lowering drug, Lapaquistat acetate decreased plasma cholesterol and triglyceride levels, by lowering lipoproteins containing apoB100.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-061834 5 mg $498 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
White to off-white crystalline solid
2-[1-[2-[(3R,5S)-1-(3-acetyloxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid; (1-(2-(1-(2-carboxyoxy-1,1-dimethylethyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydrobenzo(e)(1,4)oxazepin-3-yl)acetyl)piperidin-4-yl)acetic acid; 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid; lapaquistat; TAK 475; TAK-475; TAK475
A novel squalene synthase inhibitor
Canonical SMILES:
1.Pharmacokinetics of TAK-475, a Squalene Synthase Inhibitor, in Rats and Dogs.
Ebihara T1, Teshima K1, Kondo T1, Tagawa Y1, Moriwaki T1, Asahi S1. Drug Res (Stuttg). 2016 Feb 2. [Epub ahead of print]
The pharmacokinetics of TAK-475 (lapaquistat acetate), a squalene synthase inhibitor, was investigated in rats and dogs. After oral administration of 14C-labeled TAK-475 ([14C]TAK-475) to rats and dogs at a dose of 10 mg/kg, the bioavailability (BA) was relatively low at 3.5 and 8.2%, respectively. The main component of the radioactivity in the plasma was M-I, which has a comparable pharmacological activity to TAK-475 in vitro. The radioactivity in the portal plasma after intraduodenal administration of [14C]TAK-475 to portal vein-cannulated rat was also mainly M-I, suggesting that most of the TAK-475 was hydrolyzed to M-I during the permeable process in the intestine. The concentrations of M-I in the liver, the main organ of cholesterol biosynthesis, were much higher than those in the plasma after oral administration of [14C]TAK-475 to rats. The main elimination route of the radioactivity was fecal excretion after oral administration of [14C]TAK-475 to rats and dogs, and the absorbed radioactivity was mainly excreted via the bile as M-I in rats.
2.Novel nonstatin strategies to lower low-density lipoprotein cholesterol.
Davidson MH1. Curr Atheroscler Rep. 2009 Jan;11(1):67-70.
There remains an unmet need to reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients who are maximized on current therapy or intolerant to statins. Several novel agents have been developed to lower LDL-C, either as monotherapy or in combination with statins. These novel therapies include squalene synthase inhibitors, microsomal triglyceride transfer protein inhibitors, and antisense apolipoprotein B. Although each of these novel therapies effectively lowers LDL-C, challenges remain in the clinical development to assess long-term safety.
3.Characterization of Transporters in the Hepatic Uptake of TAK-475 M-I, a Squalene Synthase Inhibitor, in Rats and Humans.
Ebihara T1, Takeuchi T1, Moriya Y1, Tagawa Y1, Kondo T1, Moriwaki T1, Asahi S1. Drug Res (Stuttg). 2016 Mar 24. [Epub ahead of print]
TAK-475 (lapaquistat acetate) is a squalene synthase inhibitor and M-I is a pharmacologically active metabolite of TAK-475. Preclinical pharmacokinetic studies have demonstrated that most of the dosed TAK-475 was hydrolyzed to M-I during the absorption process and the concentrations of M-I in the liver, the main organ of cholesterol biosynthesis, were much higher than those in the plasma after oral administration to rats. In the present study, the mechanism of the hepatic uptake of M-I was investigated.The uptake studies of 14C-labeled M-I into rat and human hepatocytes indicated that the uptakes of M-I were concentrative, temperature-dependent and saturable in both species with Km values of 4.7 and 2.8 μmol/L, respectively. M-I uptake was also inhibited by cyclosporin A, an inhibitor for hepatic uptake transporters including organic anion transporting polypeptide (OATP). In the human hepatocytes, M-I uptake was hardly inhibited by estrone 3-sulfate as an inhibitor for OATP1B1, and most of the M-I uptake was Na+-independent.
4.Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia.
Seiki S1, Frishman WH. Cardiol Rev. 2009 Mar-Apr;17(2):70-6. doi: 10.1097/CRD.0b013e3181885905.
Hypercholesterolemia is a major risk factor for the development of atherosclerotic vascular diseases. The most popular agents for cholesterol reduction are the statin drugs, which are competitive inhibitors of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the primary rate-limiting enzyme in the hepatic biosynthesis of cholesterol. Although relatively safe and effective, the available statins can cause elevations in liver enzymes and myopathy. Squalene synthase is another enzyme that is downstream to HMG-CoA reductase in the cholesterol synthesis pathway and modulates the first committed step of hepatic cholesterol biosynthesis at the final branch point of the cholesterol biosynthetic pathway. Squalene epoxidase and oxidosqualene cyclase are other enzymes that act distally to squalene synthase. Pharmacologic inhibitors of these downstream enzymes have been developed, which may reduce low-density lipoprotein cholesterol and reduce the myopathy side effect seen with upstream inhibition of HMG-CoA.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 201530-41-8 Deferasirox

(CAS: 201530-41-8)

Deferasirox effectively chelates iron from Rhizopus oryzae and demonstrates cidal activity in vitro against 28 of 29 clinical isolates of Mucorales at concentra...

CAS 13309-08-5 3PO

(CAS: 13309-08-5)

3PO is originally reported to inhibit PFKFB3 (IC50 = 25 μM), with the potential to inhibit cancer cell proliferation. The addition of selective inhibitors of au...

CAS 477-90-7 Bergenin

(CAS: 477-90-7)

Bergenin is trihydroxybenzoic acid glycoside and the C-glycoside of 4-O-methyl gallic acid.It shows a potent immunomodulatory effect.

CAS 404844-02-6 N-Desmethyl Imatinib

N-Desmethyl Imatinib
(CAS: 404844-02-6)

A metabolite of Gleevec, a tyrosine kinase inhibitor.

CAS 127-65-1 Chloramine-T

(CAS: 127-65-1)

Chloramine-T could be commonly used as decolorizer, sanitizer and detergent in sorts of chemical areas.

(CAS: 115088-06-7)

SPDB, a pyridyldithioyl compound, has been found to link to DM4 conjugates and probably influence the releasement of cytotoxic metabolitesin.

CAS 75450-34-9 CGP 37157

CGP 37157
(CAS: 75450-34-9)

CGP 37157 is a a selective sodium-calcium exchanger inhibitor with IC50 value of 0.36 μM in isolated mitochondria. It does not affect channels, exchangers, or A...

CAS 306-40-1 Succinylcholine

(CAS: 306-40-1)

Succinylcholine is a medication used to induce muscle relaxation and short-term paralysis used to limited to short-term muscle relaxation in anesthesia and inte...

CAS 17528-72-2 Tetrahydrobiopterin

(CAS: 17528-72-2)

Tetrahydrobiopterin, a pteridin derivative, has been found to be a cofactor to form nitric oxide and neurotransmitters serotonin.

CAS 16200-50-3 PYR-0503

(CAS: 16200-50-3)

PYR-0503, a pyrrole compound, could be commonly used in production of sorts of important compounds like some anticancer drugs and porphyrins.

(CAS: 862501-61-9)

Bisegliptin is an antidiabetic agent, but no detailed information has been published yet.

CAS 481-46-9 Ginkgetin

(CAS: 481-46-9)

Ginkgetin is a natural biflavonoid isolated from leaves of Ginkgo biloba L. According to reports, it has anti-inflammatory and anti-cancer effects.

CAS 345909-26-4 Taurocholic Acid Sodium Salt Hydrate

Taurocholic Acid Sodium Salt Hydrate
(CAS: 345909-26-4)

Choleretic; Its sodium salt is a bile salt formed in the liver by conjugation of cholic acid with taurine that is involved in the emulsification of lipids used ...

CAS 938448-87-4 Bucladesine calcium salt

Bucladesine calcium salt
(CAS: 938448-87-4)

Bucladesine calcium salt is a membrane permeable selective activator of PKA. It is absorbed very rapidly and almost completely when the aqueous solution is appl...

CAS 59-67-6 Nicotinic Acid

Nicotinic Acid
(CAS: 59-67-6)

Nicotinic Acid is a water-soluble vitamin belonging to the vitamin B family.

CAS 103-16-2 Monobenzone

(CAS: 103-16-2)

Monobenzone is a compound used as a topical agent for medical depigmentation.The topical application of monobenzone in animals decreases the excretion of melani...

CAS 66952-49-6 Methasulfocarb

(CAS: 66952-49-6)

Methasulfocarb is a fungicide compound.

CAS 697797-51-6 UAMC00039 dihydrochloride

UAMC00039 dihydrochloride
(CAS: 697797-51-6)

UAMC00039 dihydrochloride is a potent, reversible and competitive dipeptidyl peptidase II inhibitor (IC50= 0.48 nM) with selectivity against DPP-9, DPP-8 and DP...

CAS 141206-42-0 N-(n-Butyl)deoxygalactonojirimycin

(CAS: 141206-42-0)

Lucerastat is a selective α-D-galactosidase inhibitor. It can prevent glucosylceramide biosynthesis both in vitro and in mouse models of lysosome storage disord...

CAS 52-67-5 Penicillamine

(CAS: 52-67-5)

Penicillamine is used as an antirheumatic and as a chelating agent in Wilson’s disease.

Chemical Structure

CAS 189060-13-7 Lapaquistat acetate

Quick Inquiry

Verification code

Featured Items